News Article | May 17, 2017
— Market Highlights The global genetic testing market has been evaluated as rapidly growing and is expected to grow further. Benefits such as predicting risk of diseases, genetic abnormalities along with prenatal and newborn congenital abnormalities etc. had increased the market of global genetic testing globally. Global genetic testing market is growing rapidly post 2016 due to an increasing number of cases of newborn, prenatal and other molecular abnormalities. This market size is expected to increase by USD of 8.8 billion by the end of 2022. Global Genetic Testing Market is expected to grow at 9.6% CAGR From 2016-2022 Key players of Global Genetic Testing Market: • Abbott (U.S.) • AutoGenomics (Ireland) • Biocartis (Switzerland) • Bio-Rad (U.S.) • Cepheid (U.S.) • EKF Diagnostics (U.K.) • Elitech Group (France) • IntegraGen (France) • Interpace Diagnostics (U.S.) • Myriad Genetics (U.S.) • Perkin Elmir (U.S.A.) • Quest Diagnostic (U.S.) • Roche Diagnostic • WaferGen Biosystem and others With technological advancement in recent years, the genetic testing device market has become one of the most important market in the healthcare industry. Genetic testing allows diagnosis of any disease as well as predicting its risk of affecting any individual. Genetic testing helps in delivering customized health services to the patient hence is also known as personalized medicine. It allows in determining bloodlines, diseases, inherited disorders and even gender and health of the fetus. Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Genetic Testing Market Research Report- Global Forecast To 2022’’ Commenting on this report, an analyst from Market Research Future (MRFR)’s team said: “The market for genetic testing is growing rapidly due to increasing demand of newborn and prenatal screening to detect congenital abnormalities and other molecular disorder; moreover these are expected to continue their growth in the coming future. There are various factors and opportunities which help the global genetic testing market to grow, major driving factors includes innovations and technological advancements for diagnosing as well as increasing cases of prenatal and newborn congenital abnormalities. Some factors which hamper the growth of genetic testing market is high cost involved in the research and development process required for developing new technologies. Segments: Based on methods of testing • cytogenetic, • biochemical • molecular. Based on techniques used in screening • PCR, • southern blotting, • ligation and others. on the basis of application • screening, • diagnostic testing, • prenatal testing, • forensic testing, • parental testing and others. Similarly on the basis of end users • hospitals • research labs and centers • institutions and others etc. List of Tables Table 1 Global Genetic Testing Market, By Methods, 2013-2022 (Usd Million) Table 2 Global Genetic Testing Market, By Techniques, 2013-2022 (Usd Million) Table 3 Global Genetic Testing Market By Application 2013-2022 (Usd Million) Table 4 Global Genetic Testing Market, By End Users 2013-2022 (Usd Million) Continue…. List of Figures Figure 1 Research Process Figure 2 Porters Five Forces Model Figure 3 Global Genetic Testing Market Market, By Methods Figure 4 Global Genetic Testing Market, By Techniques Figure 5 Global Genetic Testing Market, By Application Continue…. Related Report Global Organic Baby Food Market Information- by Ingredient (fruits, vegetables, grains & cereals, meat, and dairy), by Product type (baby milks, baby cereals dry meals, finger foods, baby drinks & other organic baby foods), by Region - Forecast to 2027. Know more about this report @ https://www.marketresearchfuture.com/reports/organic-baby-food-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com
News Article | December 7, 2016
— The analysts forecast the global tissue diagnostics market to grow at a CAGR of 11.59% during the period 2016-2020. Tissue diagnostics involves the diagnosis of diseases or analysis of the biological causes of the disease by extracting and analyzing a specific tissue. It has a broad range of applications in clinical research, clinical diagnostics, and cell biology. It is considered one of the most accurate techniques for the diagnosis of inflammatory conditions. Medical specialists particularly use tissue diagnostics in the area of molecular biology for cancer screening, therapy selection, diagnosis, and relapse monitoring. It helps in the screening and diagnosis of lymphoma, melanoma, leukemia, and breast, ovarian, cervical, head and neck, pancreatic, non-small cell lung, colorectal, brain, prostate, lung, and endometrial cancers. Pathologists use different technologies such as in situ hybridization (ISH), immunohistochemistry (IHC), special staining, and digital pathology and related methods including core biopsy, fine needle aspiration cytology, and open biopsy to study and diagnose cells. For more information or any query mail at firstname.lastname@example.org The report covers the present scenario and the growth prospects of the global tissue diagnostics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of diagnostic devices based on the following techniques: The market is divided int the following segments based on geography: • Americas • APAC • EMEA The report, Global Tissue Diagnostics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors • 20/20 GeneSystems • Abcam • AdnaGen • Advanced Cell Diagnostics • Affymetrix • Agendia • AutoGenomics • AVIVA BioSciences • Biocare Medical • Biocartis • Cancer Genetics • ELITechGroup • Enzo Biochem • Epic Sciences • Fluidigm • HORIBA Medical • Janssen Diagnostics • Olympus Diagnostics Systems Group • Omnyx (a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, US) • Oxford Gene Technology • PANAGENE • Protea Biosciences Group • Sakura Finetek Market driver • Implementation by new customers • For a full, detailed list, view our report Market challenge • Insurance coverage and reimbursement issues • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? PART 06: Reimbursement and coverage: An overview • Current scenario: Validating diagnostic tests • Reimbursement structure in US • Reimbursement structure in EU • Prevailing issues of reimbursement policies PART 08: Market segmentation by technology • Global tissue diagnostics market by advanced staining • Global tissue diagnostics market by digital pathology • Global tissue diagnostics market by preanalytical and routine staining PART 09: Market segmentation by product • Global tissue diagnostics market segmentation by consumables • Global tissue diagnostics market segmentation by instruments For more information or any query mail at email@example.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com
PubMed | AutoGenomics, Centers for Disease Control and Prevention, Indiana University, Coriell Institute for Medical Research and 3 more.
Type: Journal Article | Journal: The Journal of molecular diagnostics : JMD | Year: 2015
Pharmacogenetic testing is increasingly available from clinical laboratories. However, only a limited number of quality control and other reference materials are currently available to support clinical testing. To address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and the Coriell Cell Repositories, has characterized 137 genomic DNA samples for 28 genes commonly genotyped by pharmacogenetic testing assays (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, and VKORC1). One hundred thirty-seven Coriell cell lines were selected based on ethnic diversity and partial genotype characterization from earlier testing. DNA samples were coded and distributed to volunteer testing laboratories for targeted genotyping using a number of commercially available and laboratory developed tests. Through consensus verification, we confirmed the presence of at least 108 variant pharmacogenetic alleles. These samples are also being characterized by other pharmacogenetic assays, including next-generation sequencing, which will be reported separately. Genotyping results were consistent among laboratories, with most differences in allele assignments attributed to assay design and variability in reported allele nomenclature, particularly for CYP2D6, UGT1A1, and VKORC1. These publicly availablesamples will help ensure the accuracy of pharmacogenetic testing.
News Article | November 2, 2016
— Genetic tests have revolutionized the molecular diagnostics market. Factors such as growing awareness, technological advancements in genetic sequencing, advancement in DNA analysis, early diagnosis and personalized medicines are driving the market growth. Growing incidence of genetic diseases and screening new-born babies or embryos for genetic defects will provide wider opportunities. The lack of governmental regulation and the potential misinterpretation of genetic information as well as ethical issues will challenge the market. Lack of reimbursement & medical coverage and high cost of the procedures will restrain the market growth. Diagnostic testing and Newborn screening application have projected to grow in the market. The Carrier Testing market is expected to witness the highest growth during the forecast period and Cancer genetic testing commanding the largest market share. North America dominated the global market followed by Europe. Asia Pacific is the fastest growing market led by China. Some of the key players in global Genetic Testing market are Abbott Laboratories, Biocartis SA, Applied Biosystems Inc, Celera Group, AutoGenomics Inc, Roche Diagnostics Limited, IntegraGen S.A, Transgenomic, Inc, Molecular Inc, Luminex Corporation , Quest Diagnostics Inc, PerkinElmer Inc, BioRad Laboratories, ELITech Group, Agilent Technologies Inc and Thermo Fisher Scientific. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/
News Article | December 5, 2016
According to Stratistics MRC, the Global Genetic Testing market accounted for $3.5 billion in 2015 and is expected to reach $6.0 billion by 2022 growing at a CAGR of 8.2% from 2015 to 2022. Genetic tests have revolutionized the molecular diagnostics market. Factors such as growing awareness, technological advancements in genetic sequencing, advancement in DNA analysis, early diagnosis and personalized medicines are driving the market growth. Growing incidence of genetic diseases and screening new-born babies or embryos for genetic defects will provide wider opportunities. The lack of governmental regulation and the potential misinterpretation of genetic information as well as ethical issues will challenge the market. Lack of reimbursement & medical coverage and high cost of the procedures will restrain the market growth. Diagnostic testing and Newborn screening application have projected to grow in the market. The Carrier Testing market is expected to witness the highest growth during the forecast period and Cancer genetic testing commanding the largest market share. North America dominated the global market followed by Europe. Asia Pacific is the fastest growing market led by China. Some of the key players in global Genetic Testing market are Abbott Laboratories, Biocartis SA, Applied Biosystems Inc, Celera Group, AutoGenomics Inc, Roche Diagnostics Limited, IntegraGen S.A, Transgenomic, Inc, Molecular Inc, Luminex Corporation , Quest Diagnostics Inc, PerkinElmer Inc, BioRad Laboratories, ELITech Group, Agilent Technologies Inc and Thermo Fisher Scientific. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
News Article | November 23, 2016
Genetic testing is widely used for detection of diseases that are related to genotype, phenotype or mutation. Also, genetic testing is done to detect karyotype for clinical purposes. Popularity of genetic testing is increasing due to various advantages offered by this procedure such as detection of genetic abnormalities in early gestation period of about 8 to 10 weeks. In addition, it also helps to determine the sex the fetus. Genetic testing market is growing at a significant rate due to increasing awareness and discoveries in the field. Of all the tests performed for genetic testing, screening for genetic mutations with Cystic Fibrosis Trans-Membrane Conductance Regulator (CFTR) gene is most widely performed. North America dominates the global market for genetic testing due to increasing prevalence of diseases by genetic disorders and high technological advancement in the region. Europe, followed by Asia, is expected to show high growth rate in the next few years in genetic testing market. China and India are expected to be the fastest growing genetic testing markets in Asian region. Some of the key driving forces for genetic testing market in emerging countries are increasing R&D investment, large pool of patients and rising government funding. Various factors such as advancements in genetic testing technologies, increasing prevalence of genetic diseases and growing awareness are driving the global genetic testing market. In addition, government initiatives and increased R&D activities in the field have been driving the genetic testing market. However, high cost involved, lack of experienced professionals and stringent regulations in some regions is restraining the global genetic testing market. Innovation of some new techniques for genetic testing, increased efficiency and accuracy are expected to offer good opportunities for global genetic testing market. In addition, emerging markets hold good potential for growth of genetic testing market due to rising patient pool and growing awareness in these regions. Some of the major trends that have been observed in the genetic testing market are shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology. Some of the major companies dealing in genetic testing market are Abbott Laboratories, BioRad Laboratories, Abbott Molecular Inc., AutoGenomics Inc., Celera Group, PerkinElmer Inc., Quest Diagnostics Inc., ELITech Group, Roche Diagnostics Corp., Applied Biosystems Inc., Roche Molecular Diagnostics Inc., Transgenomic Inc. and others.
Munson E.,Wheaton Franciscan Laboratory |
Munson E.,University of Wisconsin - Milwaukee |
Kroeger L.,Wheaton Franciscan Laboratory |
Balzer S.,Wheaton Franciscan Laboratory |
And 5 more authors.
Journal of Clinical Microbiology | Year: 2014
Assessment of 4,056 cytology collections by Cervista HPV HR and APTIMA HPV yielded 88.7% concordance, with increased detection by Cervista in patients with atypical squamous cells of undetermined significance (ASC-US) and patients negative for intraepithelial lesions and malignancy (NILM) (P<0.02). Both assays detected>91.7% of cervical intraepithelial neoplasia grade 2(CIN2) lesions. A total of 262 specimens demonstrated luminescence within all three Cervista oligonucleotide mixtures (triple positive). APTIMA HPV and PCR-based microarray confirmed triple-positive results at rates of 7.3% and 5.9%, respectively. Copyright © 2014, American Society for Microbiology.
Sistonen J.,University of Bern |
Smith C.,AutoGenomics |
Fu Y.-K.,AutoGenomics |
Largiader C.R.,University of Bern
Clinica Chimica Acta | Year: 2012
Background: Chemotherapeutic use of 5-fluorouracil (5FU) is compromised by 10-20% of patients developing severe toxicity. Recently described genetic variation in dihydropyrimidine dehydrogenase (. DPYD) has been shown to be a major predictor of 5FU toxicity. Here, we describe a new genotyping assay for routine clinical use that covers all the major DPYD risk variants. Methods: Genomic regions targeting DPYD risk variants (c.1129-5923C>G, c.1679T>G/A, c.1905+1G>A, c.2846A>T) and additional markers (c.234-123G>C, c.496A>G, c.775A>G) were amplified in a multiplex PCR reaction. The subsequent steps including allele-specific primer extension, hybridization of the primers to a microarray, scanning of the array, and data analysis were automated within the INFINITI® Analyzer (AutoGenomics). The assay was validated by analyzing 107 blood samples obtained from patients previously re-sequenced for the DPYD. Results: The genotypes obtained with the developed assay were 100% concordant with the re-sequencing. The procedure is suitable for routine clinical use since the results are obtained within one day. For heterozygous risk variant carriers (~. 7% of Europeans), the treatment can be adjusted by 5FU dose reduction, whereas carriers of two risk alleles should be treated with an alternative therapy. Conclusions: The developed assay provides a novel tool to improve the safety of commonly used 5FU-based chemotherapies. © 2012 Elsevier B.V.